Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase

Journal of Medicinal Chemistry

Volumn 50, Issue 20, 2007, Pages 4909-4916

  Leonetti, Francesco ^a   Capaldi, Carmelida ^a   Pisani, Leonardo ^a   Nicolotti, Orazio ^a   Muncipinto, Giovanni ^a   Stefanachi, Angela ^a   Cellamare, Saverio ^a   Caccia, Carla ^b   Carotti, Angelo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Newron Pharmaceuticals   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 CHLOROBENZOIC ACID; 3 CHLOROBENZYLOXYALANINAMIDE; 3 CHLOROBENZYLOXYSERINAMIDE; ALANINE DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIPARKINSON AGENT; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; SAFINAMIDE; SAFINAMIDE DERIVATIVE; SERINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN MITOCHONDRION; DRUG BINDING SITE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENANTIOSELECTIVITY; ENZYME INHIBITION; IC 50; PARKINSON DISEASE; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ALANINE; AMIDES; ANIMALS; BENZYLAMINES; BINDING SITES; ISOENZYMES; MITOCHONDRIA; MODELS, MOLECULAR; MONOAMINE OXIDASE INHIBITORS; PROTEIN BINDING; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES;

EID: 34948857434     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070725e     Document Type: Article

References (39)

1. Tipton, K. F. Enzymology of Monoamine Oxidase. Cell Biochem. Funct. 1986, 4, 79-87.
2. Yamada, M.; Yasuhara, H. Clinical Pharmacology of MAO Inhibitors: Safety and Future. Neurotoxicology 2004, 25, 215-221.
3. Johnston, J. P. Some Observation upon a New Inhibitor of Monoamine Oxidase in Brain Tissue. Biochem. Pharmacol. 1968, 17, 1285-1297.
4. (a) Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D. E.; Mattevi, A. Structure of Human Monoamine Oxidase B, a Drug Target for a Treatment of Neurological Disorders. Nat. Struct. Biol. 2002, 9, 22-26.
5. (b) Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmonson, D. E.; Mattevi, A. Insights into the Mode of Inhibition of Human Mitochondrial Monoamine Oxidase B from High-Resolution Crystal Structures. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9750-9755.
6. Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. Structure of Rat Monoamine Oxidase A and Its Specific Recognitions for Substrates and Inhibitors. J. Mol. Biol. 2004, 338, 103-114.
7. Grimsby, J.; Ian, N. C.; Neve, R.; Chen, K.; Shih, J. C. Tissue Distribution of Human Monoamine Oxidase-A and Oxidase-B Messenger-RNA. J. Neurochem. 1990, 55, 1166-1169.
8. Youdim, M. B.; Riederer, P. F. A Review of Mechanisms and Role of Monoamine Oxidase Inhibitors in Parkinson's Disease. Neurology 2004, 63 (Suppl. 2), S32.
9. Fowler, C. J.; Ross, S. B. Selective Inhibitors of Monoamine Oxidase A and B: Biochemical, Pharmacological and Clinical Properties. Med. Res. Rev. 1984, 4, 323-358.
10. Kyburz, E. New Developments in the Field of MAO Inhibitors. Drug News Perspect. 1990, 3, 592-599.
11. Drukarch, B.; van Muiswinkel, F. L. Drug Treatment of Parkinson's Disease. Time for Phase II. Biochem. Pharmacol. 2000, 59, 1023-1031.
12. Riederer, P.; Danielczyk, W.; Grunblatt, E. Monoamine Oxidase-B Inhibition in Alzheimer's Disease. Neurotoxicology 2004, 25, 271-277.
13. Pevarello, P.; Bonsignori, A.; Dostert, P.; Heidempergher, F.; Pinciroli, V.; Colombo, M.; McArthur, R. A.; Salvati, P.; Post, C.; Fariello, R. G.; Varasi, M. Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalky)amino]alkanamide Derivatives. J. Med. Chem. 1998, 41, 579-590.
14. Stocchi, F.; Arnold, G.; Onofrj, M.; Kwiecinski, H.; Szczudlik, A.; Thomas, A.; Bonuccelli, U.; Van Dijk, A.; Cattaneo, C.; Sala, P.; Fariello, R. G. Improvement of Motor Function in Early Parkinson Disease by Safinamide. Neurology 2004, 63, 746-748.
15. Marzo, A.; Dal Bo, L.; Ceppi Monti, N.; Crivelli, F.; Ismaili, S.; Caccia, C.; Cattaneo, C.; Fardello, R. G. Pharmacokinetics and Pharmacodynamics of Safinamide, a Neuroprotectant with Antiparkinsonian and Anticonvulsant Activity. Pharmacol. Res. 2004, 50, 77-85.
16. Chazot, P. L. Safinamide (Newron Pharmaceuticals). Curr. Opin. Invest. Drugs 2001, 2, 809-813.
17. Caccia, C.; Maj, R.; Calabresi, M.; Maestroni, S.; Faravelli, L.; Curatolo, L.; Salvati, P.; Fariello, R. G. Safinamide: From Molecular Targets to a New Anti-Parkinson Drug. Neurology 2006, 67, S18-23.
18. (a) Kneubühler, S.; Carta, V.; Altomare, C.; Carotti, A.; Testa, B. Synthesis and Monoamine Oxidase Inhibitors Activity of 3-Substituted 5H-Indeno[1,2-c]pyridazines. Helv. Chim. Acta 1993, 76, 1956-1963.
19. (b) Kneubühler, S.; Thull, U.; Altomare, C.; Carta, V.; Gaillard, P.; Carrupt, P.-A.; Carotti, A.; Testa, B. Inhibition of Monoamine Oxidase-B by 5H-Indeno[1,2-c]pyridazines. Biological Activities, Quantitative Structure-Activity-Relationships (QSARs) and 3D-QSARs. J. Med. Chem. 1995, 38, 3874-3883.
20. (c) Thull, U.; Kneubühler, S.; Gaillard, P.; Carrupt, P.-A.; Testa, B.; Altomare, C.; Carotti, A.; Jenner, P.; McNaught, K. S. P. Inhibition of Monamine Oxidase by Isoquinoline Derivatives: Qualitative and 3D-Quantitative Structure-Activity Relationships. Biochem. Pharmacol. 1995, 50, 869-877.
21. (d) Altomare, C.; Cellamare, S.; Summo, L.; Catto, M.; Carotti, A.; Thull, U.; Carrupt, P.-A.; Testa, B.; Stöckli-Evans, H. Inhibition of Monoamine Oxidase-B by Condensed Pyridazines and Pyrimidines; Effects of Lipophilicity and Structure-Activity Relationships. J. Med. Chem. 1998, 41, 3812-2820.
22. Carotti, A.; Carrieri, A.; Chimichi, S.; Boccalini, M.; Cosimelli, B.; Gnerre, C.; Carotti, A.; Carrupt, P.-A.; Testa, B. Natural and Synthetic Geiparvarins Are Strong and Selective MAO-B Inhibitors. Synthesis and SAR Studies. Bioorg. Med. Chem. Lett. 2002, 12, 3551-3555.
23. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.-A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of Monoamine Oxidases by Functionalized Coumarin Derivatives: Biological Activities, QSARs, and 3D-QSARs. J. Med. Chem. 2000, 43, 4747-4758.
24. Brühlmann, C.; Ooms, F.; Carrupt, P.-A.; Testa, B.; Catto, M.; Leonetti, F.; Altomare, C.; Carotti, A. Coumarin Derivatives as Dual Inhibitors of Acetylcholinesterase and Monoamine Oxidase. J. Med. Chem. 2001, 44, 3195-3198.
25. Novaroli, L.; Reist, M.; Favre, E.; Carotti, A.; Catto, M.; Carrupt, P.-A. Human Recombinant Monoamine Oxidase B as Reliable and Efficient Enzyme Source for Inhibitor Screening. Bioorg. Med. Chem. 2005, 13, 6212-6127.
26. Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De Marco, A.; Rose, S.; Jenner, P.; Testa, B. Lipophilicity Plays a Major Role in Modulating Monoamine Oxidase B (MAO-B) Inhibition by 7-Substituted Coumarins. Chem. Biodiversity 2006, 3, 134-149.
27. Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A.; Soto-Otero, R.; Mendez-Alvarez, E.; Carotti, A. Structural Insights into Monoamine Oxidase Inhibitory Potency and Selectivity of 7-Substituted Coumarins from Ligand- and Target-Based Approaches. J. Med. Chem. 2006, 49, 4912-4925.
28. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.; Carrupt, P. A.; Reist, M. Impact of Species-Dependent Differences on Screening, Design, and Development of MAO B Inhibitors J. Med. Chem. 2006, 49, 6264-6272.
29. (a) Thompson, L. A.; Ellman, J. A. Synthesis and Applications of Small Molecule Libraries. Chem. Rev. 1996, 96, 555-600.
30. (b) Nefzi, A.; Ostresh, J. M.; Houghten, R. A. The Current Status of Heterocyclic Combinatorial Libraries. Chem. Rev. 1997, 97, 449-472.
31. (c) Bunin, B. A.; Dener, J. M.; Livingston, D. A. Application of Combinatorial and Parallel Synthesis to Medicinal Chemistry. Annu. Rep. Med. Chem. 1999, 34, 267-286.
32. (d) Franzén, R. G. Recent Advances in the Preparation of Heterocycles on Solid Support: A Review of the Literature. J. Comb. Chem. 2000, 2, 195-214.
33. Dolle, R. E. Comprehensive Survey of Combinatorial Library Synthesis: 2001. J. Comb. Chem. 2002, 4, 369-418.
34. Kate, S. A., Albericio, F., Eds. Solid-Phase Synthesis: A Practical Guide; Marcel Dekker: New York, 2000.
35. Ley, S. V.; Baxendale, I. R.; Bream, R. N.; Jackson, P. S.; Leach, A. G.; Longbottom, D. A.; Nesi, M.; Scott, J. S.; Storer, R. I.; Taylor, S. J. Multi-Step Organic Synthesis Using Solid-Supported Reagents and Scavengers: A New Paradigm in Chemical Library Generation J. Chem. Soc., Perkin Trans. 1 2000, 3815-4195.
36. Bhattacharyya, S.; Fan, L.; Vo, L.; Labadie, J. Titanium(IV) Isopropoxide Mediated Solution Phase Reductive Amination on an Automated Platform: Application in the Generation of Urea and Amide Libraries. Comb. Chem. High Throughput Screening 2000, 3, 117-124.
37. Hughes, D. L. Progress in the Mitsunobu Reaction. Org. Prep. Proced. Int. 1996, 28, 127-164.
38. Robinson, D. S.; Lovenberg, W.; Keiser, H. Sjoerdsma Effects of Drugs on Human Blood Platelet and Plasma Amine Oxidase Activity in Vitro and in Vivo. Biochem. Pharmacol. 1968, 17, 109-119.
39. Westhead, D. R.; Clark, D. E.; Murray, C. W. A Comparison of Heuristic Search Algorithms for Molecular Docking. J. Comput.-Aided Mol. Des. 1997, 11, 209-228.